AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31096780 — intervention group
Group type: EXPERIMENTAL
Intervention: Supporting Teens with Autism on Relationships program (both groups)
Number of subjects: 84
Study 31538590 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA + AA supplementation (200 mg DHA + 200 mg AA daily for 180 days)
Number of subjects: 377
Study 31538590 — intervention group
Group type: COMPARATOR
Intervention: Placebo (400 mg corn oil daily for 180 days)
Number of subjects: 377
Study 27269294 — intervention group
Group type: EXPERIMENTAL
Intervention: Cx611 (1 million/kg)
Number of subjects: 53
Study 27269294 — intervention group
Group type: EXPERIMENTAL
Intervention: Cx611 (2 million/kg)
Number of subjects: 53
Study 27269294 — intervention group
Group type: EXPERIMENTAL
Intervention: Cx611 (4 million/kg)
Number of subjects: 53
Study 27269294 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 25445156 — intervention group
Group type: EXPERIMENTAL
Intervention: IG-IMRT
Number of subjects: 18
Study 25445156 — intervention group
Group type: COMPARATOR
Intervention: 3D-CRT
Number of subjects: 18
Study 25445156 — intervention group
Group type: COMPARATOR
Intervention: SBRT (positive control)
Number of subjects: 18
Study 25445156 — intervention group
Group type: EXPERIMENTAL
Intervention: All participants
Number of subjects: 18
Study 25445156 — intervention group
Group type: EXPERIMENTAL
Intervention: Doses ≥ 35 Gy
Number of subjects: 18
Study 23829690 — intervention group
Group type: EXPERIMENTAL
Intervention: Latina-targeted Pap smear and mammogram public service announcements
Number of subjects: 1419
Study 23829690 — intervention group
Group type: COMPARATOR
Intervention: General-market messages
Number of subjects: 1419
Study 21745533 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline 1:1000
Number of subjects: 534
Study 21745533 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sodium chloride 0.9%)
Number of subjects: 534
Study 19934912 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed/lactated Ringer's
Number of subjects: 64
Study 19934912 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed/hetastarch
Number of subjects: 64
Study 19934912 — intervention group
Group type: COMPARATOR
Intervention: Standard
Number of subjects: 64
Study 16412747 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral estrogen therapy (0.625 mg of conjugated equine E per tablet; n = 27)
Number of subjects: 57
Study 16412747 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical estrogen therapy (0.625 mg conjugated equine E per 1 g vaginal cream; n = 30)
Number of subjects: 57
Study 16412747 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral estrogen therapy
Number of subjects: 57
Study 16412747 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical estrogen therapy
Number of subjects: 57
Study 15326115 — intervention group
Group type: COMPARATOR
Intervention: Silicone hydrogel contact lens
Number of subjects: 20
Study 15326115 — intervention group
Group type: COMPARATOR
Intervention: Hyper-Dk rigid contact lens
Number of subjects: 20
Study 15326115 — intervention group
Group type: COMPARATOR
Intervention: Rubbing one eye
Number of subjects: 20
Study 11424305 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based nursing documentation system (PIK group)
Number of subjects: 60
Study 11424305 — intervention group
Group type: COMPARATOR
Intervention: Paper-based system (control group)
Number of subjects: 60
Study 9690480 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH, dalteparin, Fragmin) once daily for 5 weeks
Number of subjects: 0
Study 9690480 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH, dalteparin, Fragmin) once daily for 7 days
Number of subjects: 0
Study 9690480 — intervention group
Group type: COMPARATOR
Intervention: Placebo following a 1-week LMWH treatment (once daily)
Number of subjects: 0
Study 8506906 — intervention group
Group type: EXPERIMENTAL
Intervention: Single running suture (24-bite 10-0 nylon suture)
Number of subjects: 38
Study 8506906 — intervention group
Group type: COMPARATOR
Intervention: Combined running and interrupted sutures (16-bite running 10-0 nylon suture and eight interrupted 10-0 nylon sutures)
Number of subjects: 38
Study 3319640 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine 30 mg t.d.s.
Number of subjects: 22
Study 3319640 — intervention group
Group type: COMPARATOR
Intervention: Propranolol 80 mg t.d.s.
Number of subjects: 22
Study 27251578 — intervention group
Group type: EXPERIMENTAL
Intervention: GMT+Lifelog
Number of subjects: 16
Study 27251578 — intervention group
Group type: COMPARATOR
Intervention: GMT
Number of subjects: 16
Study 27403851 — intervention group
Group type: EXPERIMENTAL
Intervention: l-Tyrosine (TYR) supplementation
Number of subjects: 0
Study 27403851 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 0
Study 25060669 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 699
Study 25060669 — intervention group
Group type: EXPERIMENTAL
Intervention: Other NSAIDs
Number of subjects: 699
Study 25060669 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 699
Study 23609389 — intervention group
Group type: EXPERIMENTAL
Intervention: Almorexant 100 mg
Number of subjects: 36
Study 23609389 — intervention group
Group type: EXPERIMENTAL
Intervention: Almorexant 200 mg
Number of subjects: 36
Study 23609389 — intervention group
Group type: EXPERIMENTAL
Intervention: Almorexant 400 mg
Number of subjects: 36
Study 23609389 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 23609389 — intervention group
Group type: COMPARATOR
Intervention: Zolpidem 10 mg
Number of subjects: 36
Study 20508184 — intervention group
Group type: EXPERIMENTAL
Intervention: Auto-titrating continuous positive airway pressure (auto-CPAP) for 2 nights, continued for 90 days for those with sleep apnea.
Number of subjects: 70
Study 20508184 — intervention group
Group type: COMPARATOR
Intervention: Control group received polysomnography at baseline and at 90 days without auto-CPAP.
Number of subjects: 70
Study 18211277 — intervention group
Group type: EXPERIMENTAL
Intervention: Personality-targeted intervention
Number of subjects: 368
Study 18211277 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 368
Study 16380825 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced emotions (joy, anger, disgust)
Number of subjects: 30
Study 16380825 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced emotions (disgust)
Number of subjects: 30
Study 16380825 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced emotions (fear/anxiety)
Number of subjects: 30
Study 12725663 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estrogen (50 microg estradiol patch weekly)
Number of subjects: 27
Study 12725663 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 12725663 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estrogen
Number of subjects: 27
Study 12725663 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal patients (healthy women)
Number of subjects: 27
Study 12725663 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with coronary disease
Number of subjects: 27
Study 10961865 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA and MTX
Number of subjects: 71
Study 10961865 — intervention group
Group type: COMPARATOR
Intervention: CsA alone
Number of subjects: 71
Study 8615489 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative ketorolac 60 mg i.v. with fentanyl 2 micrograms/kg i.v.
Number of subjects: 126
Study 8615489 — intervention group
Group type: COMPARATOR
Intervention: Control group (saline 2 mL) with fentanyl 2 micrograms/kg i.v.
Number of subjects: 126
Study 1288967 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone alone
Number of subjects: 284
Study 1288967 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone plus amikacin
Number of subjects: 284
Study 6327784 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole (200 mg daily for 4 weeks)
Number of subjects: 66
Study 6327784 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 6327784 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole (follow-up after 1 year)
Number of subjects: 66
Study 6327784 — intervention group
Group type: COMPARATOR
Intervention: Placebo (followed by topical imidazole)
Number of subjects: 66
Study 31215270 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone combined with misoprostol
Number of subjects: 25
Study 31215270 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol alone
Number of subjects: 25
Study 31215270 — intervention group
Group type: COMPARATOR
Intervention: Expectant management or surgical intervention
Number of subjects: 25
Study 30235704 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroscopy-guided acupuncture
Number of subjects: 57
Study 30235704 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture without fluoroscopy
Number of subjects: 57
Study 30235704 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Fluoroscopy-guided acupuncture and Acupuncture without fluoroscopy)
Number of subjects: 57
Study 26734954 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine (230 ml/day for women, 300 ml/day for men)
Number of subjects: 24
Study 26734954 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine
Number of subjects: 24
Study 26734954 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 24
Study 26734954 — intervention group
Group type: COMPARATOR
Intervention: Dealcoholized red wine (DRW)
Number of subjects: 24
Study 24473592 — intervention group
Group type: EXPERIMENTAL
Intervention: Child Development Accounts (CDAs) with additional financial incentives and information
Number of subjects: 2704
Study 24473592 — intervention group
Group type: EXPERIMENTAL
Intervention: Child Development Accounts (CDAs) for low-income households
Number of subjects: 2704
Study 24473592 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CDAs)
Number of subjects: 2704
Study 22848584 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyllium supplementation (6 g/day for 6 weeks)
Number of subjects: 47
Study 20704623 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus
Number of subjects: 90
Study 20704623 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 17157066 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial overdrive pacing (O)
Number of subjects: 15
Study 17157066 — intervention group
Group type: COMPARATOR
Intervention: Pacemaker rate set at 40‐50 beats per minutes (N)
Number of subjects: 15
Study 17157066 — intervention group
Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 15
Study 16045013 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg/d) + Benazepril (10 mg/d)
Number of subjects: 60
Study 16045013 — intervention group
Group type: COMPARATOR
Intervention: Benazepril (10 mg/d)
Number of subjects: 60
Study 12815796 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrogastrography (EGG) recording after a meal
Number of subjects: 67
Study 12815796 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradygastria (group I)
Number of subjects: 67
Study 12815796 — intervention group
Group type: EXPERIMENTAL
Intervention: Tachygastria (group II)
Number of subjects: 67
Study 12815796 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 67
Study 10408721 — intervention group
Group type: EXPERIMENTAL
Intervention: Photopheresis
Number of subjects: 16
Study 10408721 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 16
Study 7480098 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg)
Number of subjects: 12
Study 7480098 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine (200 mg)
Number of subjects: 12
Study 7480098 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of nifedipine (20 mg) and quinidine (200 mg)
Number of subjects: 12
Study 2110817 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-sedative antihistamine terfenadine (60 mg b.i.d.)
Number of subjects: 25
Study 2110817 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedative antihistamine clemastine (2 mg b.i.d.)
Number of subjects: 25
Study 2110817 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 117755 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 34
Study 117755 — intervention group
Group type: COMPARATOR
Intervention: Milk feeding
Number of subjects: 34
Study 29349922 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk intake at 9-10 months of age (mean 752 g/day)
Number of subjects: 0
Study 29349922 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportion of total energy intake from breast milk
Number of subjects: 0
Study 29349922 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk intake and percent of total energy intake from breast milk
Number of subjects: 0
Study 27225338 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg/kg magnesium sulfate via cardioplegic solution
Number of subjects: 120
Study 27225338 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg/kg magnesium sulfate via cardioplegic solution
Number of subjects: 120
Study 27225338 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/kg magnesium sulfate via cardioplegic solution
Number of subjects: 120
Study 27225338 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg/kg and 100 mg/kg magnesium sulfate
Number of subjects: 120
Study 27225338 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/kg magnesium sulfate
Number of subjects: 120
Study 25342641 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertive Community Treatment (ACT)
Number of subjects: 251
Study 25342641 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Treatment Order
Number of subjects: 251
Study 25342641 — intervention group
Group type: COMPARATOR
Intervention: Usual care by CMHTs
Number of subjects: 251
Study 23912367 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 40
Study 23912367 — intervention group
Group type: COMPARATOR
Intervention: Normal diet
Number of subjects: 40
Study 20403667 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral nutrition (EEN) group, initiated between 3 and 6 hours after burn
Number of subjects: 688
Study 20403667 — intervention group
Group type: COMPARATOR
Intervention: Late enteral nutrition (LEN) group, received only intravenous resuscitation in the first 48 hours
Number of subjects: 688
Study 18616780 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple combination (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%)
Number of subjects: 252
Study 18616780 — intervention group
Group type: COMPARATOR
Intervention: Hydroquinone 4% cream
Number of subjects: 252
Study 16895631 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 287
Study 16895631 — intervention group
Group type: COMPARATOR
Intervention: Control (no metformin)
Number of subjects: 287
Study 11453911 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-pulsed tunable dye laser (LPTDL, 585 nm; 5-mm spot size; 11-20 J cm(‐2) fluence)
Number of subjects: 62
Study 11453911 — intervention group
Group type: EXPERIMENTAL
Intervention: Flashlamp-pumped dye laser (FPDL, 585 nm; 7-mm spot size; 5.75-7.0 J cm(‐2) fluence)
Number of subjects: 62
Study 11453911 — intervention group
Group type: COMPARATOR
Intervention: Both lasers at 585 nm
Number of subjects: 62
Study 10211066 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital screening system with C-arm
Number of subjects: 45
Study 10211066 — intervention group
Group type: COMPARATOR
Intervention: Analogue fluoroscopic unit and standard film‐screen radiography
Number of subjects: 45
Study 7519032 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,24(OH)2D3 ointment (tacalcitol; 4 micrograms/g)
Number of subjects: 10
Study 7519032 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2928741 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 0.075 mg twice daily
Number of subjects: 20
Study 2928741 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1410124 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (high dose: 1.1 ml. ethanol/kilogram body weight)
Number of subjects: 11
Study 1410124 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 648938 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine treatment for 12 weeks
Number of subjects: 16
Study 31419309 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine 1% applied onto the volar forearm
Number of subjects: 30
Study 31419309 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional MRI
Number of subjects: 30
Study 31419309 — intervention group
Group type: COMPARATOR
Intervention: Histamine skin prick model
Number of subjects: 30
Study 27569403 — intervention group
Group type: EXPERIMENTAL
Intervention: Printed Post-it® note
Number of subjects: 611
Study 27569403 — intervention group
Group type: COMPARATOR
Intervention: Control (without Post-it® note)
Number of subjects: 611
Study 26319612 — intervention group
Group type: EXPERIMENTAL
Intervention: biofortified gari (1 mg β‐carotene)
Number of subjects: 8
Study 26319612 — intervention group
Group type: EXPERIMENTAL
Intervention: red palm oil-fortified gari (1 mg β‐carotene)
Number of subjects: 8
Study 26319612 — intervention group
Group type: COMPARATOR
Intervention: unfortified gari (0.3 mg retinyl palmitate reference dose)
Number of subjects: 8
Study 24303604 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher mean arterial pressure (MAP) during cardiopulmonary bypass (CPB); MAP attained 77.7 ± 7.1 mmHg
Number of subjects: 248
Study 24303604 — intervention group
Group type: COMPARATOR
Intervention: Lower mean arterial pressure (MAP) during cardiopulmonary bypass (CPB); MAP attained 56.7 ± 5.0 mmHg
Number of subjects: 248
Study 24303604 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologic protocol for maintaining higher MAP
Number of subjects: 248
Study 20644943 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg q.d.
Number of subjects: 120
Study 20644943 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 100 mg q.d.
Number of subjects: 120
Study 20644943 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ASA and clopidogrel
Number of subjects: 120
Study 20644943 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 120
Study 19269773 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (up to 300mg/day)
Number of subjects: 153
Study 19269773 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50mg/day)
Number of subjects: 153
Study 19269773 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study 17589944 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiation therapy (gemcitabine and radiation dose 50.4 Gy) before surgery
Number of subjects: 47
Study 17589944 — intervention group
Group type: COMPARATOR
Intervention: Surgery only
Number of subjects: 47
Study 17589944 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiation therapy (gemcitabine and radiation dose 50.4 Gy) before surgery in ductal adenocarcinoma
Number of subjects: 47
Study 17589944 — intervention group
Group type: COMPARATOR
Intervention: Surgery only in ductal adenocarcinoma
Number of subjects: 47
Study 15140780 — intervention group
Group type: EXPERIMENTAL
Intervention: PVAC (50 micro g)
Number of subjects: 36
Study 15140780 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 15140780 — intervention group
Group type: EXPERIMENTAL
Intervention: PVAC
Number of subjects: 36
Study 12407061 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin and aspirin (group 1)
Number of subjects: 79
Study 12407061 — intervention group
Group type: COMPARATOR
Intervention: Heparin or aspirin (group 2)
Number of subjects: 79
Study 12407061 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone (group 3)
Number of subjects: 79
Study 9821562 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenic patients
Number of subjects: 24
Study 9821562 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 24
Study 7859654 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine washed (non-pregnant)
Number of subjects: 160
Study 7859654 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine washed (pregnant)
Number of subjects: 160
Study 7859654 — intervention group
Group type: COMPARATOR
Intervention: Saline washed (pregnant)
Number of subjects: 160
Study 7859654 — intervention group
Group type: COMPARATOR
Intervention: Not washed (pregnant)
Number of subjects: 160
Study 2675439 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg chlorophyll tablets thrice daily
Number of subjects: 28
Study 2675439 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 1089971 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic luteinizing hormone-releasing hormone (LH-RH) 50 μg
Number of subjects: 0
Study 1089971 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic luteinizing hormone-releasing hormone (LH-RH) 100 μg
Number of subjects: 0
Study 1089971 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic luteinizing hormone-releasing hormone (LH-RH) 1 μg
Number of subjects: 0
Study 1089971 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic luteinizing hormone-releasing hormone (LH-RH) 0.25 to 4 μg
Number of subjects: 0
Study 1089971 — intervention group
Group type: EXPERIMENTAL
Intervention: Two injections of LH-RH 90 min apart
Number of subjects: 0
Study 1089971 — intervention group
Group type: EXPERIMENTAL
Intervention: Two injections of LH-RH 30 or 45 min apart
Number of subjects: 0
Study 1089971 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower doses of LH-RH (not specified)
Number of subjects: 0
Study 31651959 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased levels of three amino acids (asparagine, homoarginine, tryptophan) and docosatrienoic acid
Number of subjects: 2298
Study 31651959 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased levels of C4-OH-carnitine, hexadecanedioate, N2,N2-dimethylguanosine, N4-acetylcytidine
Number of subjects: 2298
Study 31651959 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolite score comprising 17 metabolites
Number of subjects: 2298
Study 31651959 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolite score
Number of subjects: 2298